News on Haleon

Showing 1–1 of 1

• Earnings analysis

  Haleon Q1 2026: Pain Relief flat at -0.3% on £654m, Oral Health the standout

  Haleon Q1 2026 group organic revenue growth was 2.2%. Pain Relief came in essentially flat at -0.3% organic on £654m. Within Pain, Advil outperformed in North America driven by the No Pain More Gain campaign; Voltaren and Panadol grew in select geographies. Oral Health was the group-level standout. FY outlook reaffirmed.

  Haleon IR (Q1 2026 trading statement) · 2w ago